Adaptive Designs in Clinical Trials 2019

Adaptive Designs in Clinical Trials 2019 is organized by SMi Group Ltd and will be held from Apr 01 - 02, 2019 at Holiday Inn London - Kensington Forum, London, England, United Kingdom.

The target audience for this medical event is Biostatisticians. Clinical project managers, Clinical research advisors, Clinical Trials Directors, Clinical scientists, Statisticians, Quantitative scientists.

With the growing popularity in use and acceptance of adaptive designs in clinical trials - demonstrated most recently with the new FDA draft guidance on adaptive designs - there is a pressing need for a forum which explores this increasingly normalized medical methodology.

Hosting in depth presentations from regulatory agencies, researchers and biostatisticians, the meeting will cover how personalized medicine, platform trials, response-adaptive randomization, signature designs, estimand framework, Bayesian methods and digital innovation are revolutionizing the drug development process both in Europe and North America.

The benefits of attending:
At this year’s conference there will once again be an array of networking opportunities:
• Meet and network with key industry and thought leaders shaping state of the art adaptive design techniques
• More than 4 hours of networking during the conference days
• Engage with an array of vendors, with leading solution providers, Mevia and GCE Solutions among those exhibiting last year

Key reasons to attend:
• See how the regulatory environment for adaptive drug design is shifting across the continent with insights from the MHRA, Amgen, AstraZeneca and Berry Consulting
• Explore the therapeutic potential of adaptive designs with real-world examples from H.Lundbeck, GSK Vaccines, Pfizer and Novartis
• Listen to how the latest platform trial case studies - such as that of the EPAD project and the MS Society initiative, are impacting pharmaceutical development
• Delve into the long-standing discussion of Bayesian vs. frequentist designs
• Discover the latest research in response-adaptive designs: trials for rare diseases and looking forward

Additional details will be posted as soon as they are available.